drugset / Trial / NCT01634282
Along-term Study of OPC-262 in Patients With Type 2 Diabetes
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical study is to evaluate the safety of OPC-262 (2.5 mg and 5 mg) in patients with type 2 diabetes by long-term administration orally for 52 weeks and to evaluate the efficacy of OPC-262
Timeline
- Start
- 2009-08
- Primary completion
- 2011-06
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OPC-262 | Unknown | 2.5 mg | Oral |
| Subject | OPC-262 | Unknown | 5 mg | Oral |